Deep Track Capital, LP
Q2 2023 13F-HR/A Holdings
Net value change ($000)
-274,572
(-11.3%)
New positions
12
Sold out positions
13
Turnover %
33.6%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| GH | 53,700 | NEW |
| GPCR | 47,060 | 74.7% |
| EDIT | 28,424 | NEW |
| ANIP | 27,670 | NEW |
| AXSM | 27,609 | NEW |
| INSM | 26,325 | 23.8% |
| DVAX | 22,433 | 36.0% |
| ZURA | 20,689 | NEW |
| GERN | 19,287 | 33.1% |
| IONS | 14,992 | 14.8% |
Top Reduces (Value $000, Stocks/ETFs)
| IVERIC bio, Inc. | -158,145 | -100.0% |
| CHINOOK THERAPEUTICS, INC. | -69,450 | -100.0% |
| REATA PHARMACEUTICALS INC | -66,281 | -100.0% |
| BIIB | -55,606 | -100.0% |
| DICE Therapeutics, Inc. | -45,840 | -100.0% |
| EXEL | -37,498 | -100.0% |
| TVTX | -25,049 | -18.1% |
| PACB | -21,280 | -52.4% |
| Deciphera Pharmaceuticals, Inc. | -21,061 | -100.0% |
| JAZZ | -20,633 | -11.8% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
19,135
(0.9% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|